Stereotactic Body Radiation Therapy Versus Conventional Radiation Therapy in Medically-Inoperable Non-Small Lung Cancer Patients

Official Title

A Randomized Trial of Medically-Inoperable Stage 1 Non-small Cell Lung Cancer Patients Comparing Stereotactic Body Radiation Therapy Versus Conventional Radiation Therapy


A multi-centre randomized controlled open-label trial in medically inoperable patients with biopsy-proven early stage non-small cell lung cancer (NSCLC). Eligible and consenting patients will be randomly allocated to receive stereotactic body radiation therapy (SBRT) or conventional radiation therapy (CRT) in a 2:1 ratio. Radiation Therapy will be administered as soon as possible following randomization and subjects will be followed for 5 years post-randomization for cancer recurrence, toxicity and survival. The primary outcome is local control (LC). The trial will be conducted at 16-20 clinical centres throughout Canada.

Trial Description

Primary Outcome:

  • Local Control
Secondary Outcome:
  • Overall Survival
  • Disease-Free Survival
  • Event-Free Survival
  • Lung Cancer-Specific Survival
  • Radiation Treatment-Related Death
  • Toxicity
  • Quality of Life
  • Cost-Utility

View this trial on

Interested in this trial?

Print this page and take it to your doctor to discuss your eligibilty and treatment options. Only your doctor can refer you to a clinical trial.


Canadian Cancer Society

These resources are provided in partnership with the Canadian Cancer Society